37 results on '"Kantoff, P.W."'
Search Results
2. Imaging yield from 133 consecutive patients with prostate cancer and low trigger PSA from a single institution
3. 1773P ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era
4. 1770O Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-PC): An individual patient data (IPD) analysis of randomized controlled trials (RCTs) from the ICECaP consortium
5. Phase II study of sunitinib in men with advanced prostate cancer
6. Benchmarks for Academic Oncology Faculty
7. Re-inventing the medical treatment of advanced prostate cancer
8. 681P Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc)
9. SHORT-TERM OUTCOMES FOLLOWING ORAL HORMONAL PROSTATE CANCER THERAPIES BY PRE-EXISTING CARDIOVASCULAR CONDITIONS: A POPULATION-BASED STUDY
10. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate
11. Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)
12. P075 - SHORT-TERM OUTCOMES FOLLOWING ORAL HORMONAL PROSTATE CANCER THERAPIES BY PRE-EXISTING CARDIOVASCULAR CONDITIONS: A POPULATION-BASED STUDY
13. Duration of the Anti-Androgen in Men Undergoing 6 Months of an LHRH Agonist and Radiation Therapy for Unfavorable-Risk Prostate Cancer and the Risk of Death
14. 852P - Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)
15. Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer
16. Defining the Optimal Approach to the Patient With Postradiation Prostate-Specific Antigen Recurrence Using Outcome Data From a Prospective Randomized Trial
17. Immunotherapy for Advanced Prostate Cancer
18. Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
19. 123 Time to disease-related pain (TDRP) following sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Integrated results from three randomized phase 3 trials
20. Post-Treatment Prostate-Specific Antigen Nadir is Predictive of All-Cause Mortality: A Reanalysis of the Dana Farber Cancer Institute Radiation With or Without Androgen Deprivation Therapy Randomized Trial
21. The Impact of Genetic Variants in the Double-Stranded DNA Break Repair Pathway on Cancer Control in Men Treated with Radiation for Prostate Cancer
22. 7002 ORAL Time to Disease-related Pain After Sipuleucel-T in Asymptomatic Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC): Results From 3 Randomized Phase III Trials
23. Comorbidity, Body Mass Index, and Age and the Risk of Non-prostate Cancer-specific Mortality following a Postradiation PSA Recurrence
24. 7002 Further analysis of a Phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC)
25. 2239
26. Autoantibody Signatures in Prostate Cancer
27. Sex Steroid Hormones and the Androgen Receptor Gene CAG Repeat and Subsequent Risk of Prostate Cancer in the Prostate-Specific Antigen Era
28. The impact of anemia on psa outcome following radiation and androgen suppression therapy in patients with high-risk prostate cancer
29. Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma - a hospital cancer registry study
30. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors - multi-institutional analysis
31. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer - a potential role for T cells in angiogenesis
32. Rate of relapse following treatment for localized prostate cancer - a critical analysis of retrospective reports
33. The CAG Repeat Within the Androgen Receptor Gene and Benign Prostatic Hyperplasia
34. Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays
35. Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer
36. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program
37. 2239: The Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of a Fatal Myocardial Infarction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.